Baxter International Elects New Director and Amends Bylaws

Baxter International Inc. (BAX) disclosed the election of Brent L. Saunders to its board of directors and the departure of one existing director, according to an 8-K filed with the SEC on May 8, 2026.

The filing covers Item 5.02 on departure and election of directors, Item 5.03 on amendments to articles of incorporation or bylaws, Item 5.07 on submission of matters to a vote of security holders, and Item 9.01 on financial statements and exhibits.

Saunders joins the board of the medical products and therapies company, which maintains a global workforce and serves hospitals, clinics, and patients in more than 100 countries.

The election fills one board seat while another director has left the role. The company also adopted amendments to its bylaws. Both the board change and bylaw revisions take effect on the filing date of May 8, 2026. Prior to the filing the board operated under the previous composition and unamended bylaws; the new state replaces that structure without a stated transition period.

The board change requires Baxter to update its disclosures in subsequent SEC filings, including any proxy statements for the next annual shareholder meeting. The bylaw amendments may alter procedural thresholds for shareholder proposals, special meetings, or director nominations, triggering immediate application to any pending governance matters.

Item 5.07 indicates security holders voted on specified matters, which in turn ratifies or rejects the company's actions and sets the record for regulatory compliance deadlines under SEC rules.

This marks the latest governance update from Baxter following routine annual shareholder votes. The Form 8-K serves as the primary public record of the board transition and bylaw changes, with full exhibits attached for inspection on the SEC's EDGAR system.